{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:01:42Z","timestamp":1792033302099,"version":"4.4.0"},"reference-count":49,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Tropical Med Int Health"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>Nipah and Hendra are deadly zoonotic diseases with pandemic potential. To date, no human vaccine or monoclonal antibody (mAb) has been licensed to prevent disease caused by these pathogens. The aim of this scoping review was to identify and describe all Phase I, II, and III clinical trials of vaccine candidates or mAbs candidates designed to prevent Nipah and Hendra in humans and to compare the characteristics of the vaccine candidates to characteristics outlined in the Target Product Profile\u00a0drafted by the World Health Organisation as part of the WHO Research &amp; Development Blueprint for Action to Prevent Epidemics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We searched 23 clinical trial registries, the Cochrane Central Register of Clinical Trials, and grey literature up to June 2023 to identify vaccine and mAb candidates being evaluated in registered clinical trials. Vaccine candidate and trial characteristics were double\u2010extracted for evaluation and the vaccine candidate characteristics were compared with the preferred and critical criteria of the World Health Organisation's Target Product Profile for Nipah virus vaccine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three vaccine candidates (Hendra Virus Soluble Glycoprotein Vaccine [HeV\u2010sG\u2010V], PHV02, and mRNA\u20101215) and one mAb (m102.4) had a registered human clinical trial by June 2023. All trials were phase 1, dose\u2010ranging trials taking place in the United States of America or Australia and enrolling healthy adults. Although all vaccine candidates meet the dose regimen and route of administration criteria of the Target Product Profile, other criteria such as measures of efficacy and reactogenicity will need to be evaluated in the future as evidence becomes available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Multiple vaccine candidates and one mAb candidate have reached the stage of human clinical trials and are reviewed here. Monitoring progress during evaluation of these candidates and candidates entering clinical trials in the future can help highlight many of the challenges that remain.<\/jats:p><\/jats:sec>","DOI":"10.1111\/tmi.13979","type":"journal-article","created":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T09:04:41Z","timestamp":1709111081000},"page":"354-364","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Current progress towards prevention of <scp>Nipah<\/scp> and <scp>Hendra<\/scp> disease in humans: <scp>A<\/scp> scoping review of vaccine and monoclonal antibody candidates being evaluated in clinical trials"],"prefix":"10.1111","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-3046","authenticated-orcid":false,"given":"Valerie","family":"Rodrigue","sequence":"first","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health McGill University  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Gravagna","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Gillings School of Global Public Health University of North Carolina at Chapel Hill  Chapel Hill North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Yao","sequence":"additional","affiliation":[{"name":"School of Medicine Stanford University  Stanford California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaidehi","family":"Nafade","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health McGill University  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6353","authenticated-orcid":false,"given":"Nicole E.","family":"Basta","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Biostatistics and Occupational Health, School of Population and Global Health McGill University  Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.03.075"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-021920-113833"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.08.027"},{"key":"e_1_2_7_5_1","unstructured":"Centers for Disease Control and Prevention.Nipah Virus Distribution Map.2021[cited 2023 June]. Available from:https:\/\/www.cdc.gov\/vhf\/nipah\/outbreaks\/distribution-map.html"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2000429117"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2010"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2019.05.009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmni.2021.100873"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11121419"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.09.009"},{"key":"e_1_2_7_12_1","unstructured":"World Health Organization.NIPAH Baseline Situation Analysis 2018. [cited 2023 May]. Available from:https:\/\/cdn.who.int\/media\/docs\/default\u2010source\/documents\/health\u2010topics\/nipah\/who_nipah_baseline_situation_analysis_27jan20188b415c76\u20108649\u20104e98\u2010b18f\u201018c6134f3819.pdf?sfvrsn=8d3de3b2_1&download=true"},{"key":"e_1_2_7_13_1","unstructured":"Coalition for Epidemic Preparedness Innovations.Priority diseases.2022[cited 2023 May]. Available from:https:\/\/cepi.net\/research_dev\/priority-diseases\/"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.06.012"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2003.131159"},{"key":"e_1_2_7_16_1","unstructured":"World Health Organization.WHO Target Product Profile for Nipah virus Vaccine 2017. [cited 2022 Mar 8]. Available from:https:\/\/www.who.int\/csr\/research\u2010and\u2010development\/priority_disease_list_review_short_summary_25Jan2017.pdf"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00400-x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.12.075"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/01652176.2019.1580827"},{"key":"e_1_2_7_20_1","unstructured":"International AIDS Vaccine Initiative\/Wellcome.Supplement 2: The emerging role of monoclonal antibodies in epidemic\/pandemic preparedness and response 2020. [cited 2023 May]. Available from:https:\/\/www.iavi.org\/phocadownload\/expanding\/Expanding%20access%20to%20monoclonal%20antibody-based%20products_Supplement%202.pdf"},{"key":"#cr-split#-e_1_2_7_21_1.1","unstructured":"A Phase 1 Randomized.Placebo\u2010controlled observer\u2010blind trial to assess the safety and immunogenicity of a Nipah vaccine HeV\u2010sG\u2010V (Hendra virus soluble glycoprotein vaccine) in healthy adults: ClinicalTrials.gov identifier: NCT04199169. [updated 2022 Nov 17"},{"key":"#cr-split#-e_1_2_7_21_1.2","unstructured":"cited 2023 Jun 19]. Available from:https:\/\/clinicaltrials.gov\/study\/NCT04199169"},{"key":"#cr-split#-e_1_2_7_22_1.1","unstructured":"A Phase 1 Study to Evaluate Safety.Immunogenicity of rVSV\u2010Nipah virus vaccine candidate PHV02 in healthy adult subjects: ClinicalTrials.gov identifier: NCT05178901. [updated 2023 Nov 7"},{"key":"#cr-split#-e_1_2_7_22_1.2","unstructured":"cited 2023 Jun 19]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05178901"},{"key":"#cr-split#-e_1_2_7_23_1.1","unstructured":"A Randomized Double\u2010blind Placebo\u2010controlled Study of the Safety Tolerability.Pharmacokinetics and immunogenicity of various dosing regimens of intravenous anti\u2010Hendra virus antibody (mAb m102.4) in healthy subjects: Australian New Zealand Clinical Trials Registry identifier: ACTRN12615000395538. [updated 2016 Nov 29"},{"key":"#cr-split#-e_1_2_7_23_1.2","unstructured":"cited 2023 Jun 19]. Available from:https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=368110&isReview=true"},{"key":"#cr-split#-e_1_2_7_24_1.1","unstructured":"A Phase I Dose Escalation Open\u2010Label Clinical Trial to Evaluate Safety.Tolerability and Immunogenicity of a Nipah Virus (NiV) mRNA Vaccine mRNA\u20101215 in Healthy Adults: ClinicalTrials.gov identifier: NCT05398796. [updated 2024 Jan 5"},{"key":"#cr-split#-e_1_2_7_24_1.2","unstructured":"cited 2023 Jun 19]. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT05398796?view=record"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(19)30634-6"},{"key":"e_1_2_7_26_1","unstructured":"Coalition for Epidemic Preparedness Innovations.CEPI\u2010funded Nipah virus vaccine candidate first to reach Phase 1 clinical trial.2020[cited 2022 May]. Available from:https:\/\/cepi.net\/news_cepi\/cepi-funded-nipah-virus-vaccine-candidate-first-to-reach-phase-1-clinical-trial\/"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.07.030"},{"key":"e_1_2_7_28_1","unstructured":"The Nipah Vaccine Project.Construction of Nipah virus vaccine.2020[cited 2022 May]. Available from:https:\/\/nipahvaccine.com\/project\/construction\/"},{"key":"e_1_2_7_29_1","unstructured":"Precision Vaccinations.Nipah Virus Vaccine (PHV02).2022[cited 2022 May]. Available from:https:\/\/www.precisionvaccinations.com\/vaccines\/nipah-virus-vaccine-phv02"},{"key":"e_1_2_7_30_1","unstructured":"Centers for Disease Control and Prevention.Ebola vaccine: information about ERVEBO\u00ae 2022. [cited 2023 May]. Available from:https:\/\/www.cdc.gov\/vhf\/ebola\/clinicians\/vaccine\/index.html"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.772864"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003684"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122769119"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00284-w"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.087"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.089"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010078"},{"key":"e_1_2_7_38_1","unstructured":"World Health Organization.Weekly epidemiological record.2021[cited 2023 Jun 22]. 197\u2013216. Available from:https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/341623\/WER9622-eng-fre.pdf?sequence=1&isAllowed=y"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2018-001086"},{"key":"e_1_2_7_40_1","volume-title":"Management plan for Nipah outbreak in Kozhikode \u2013 5th Sept 2021","author":"Health & Family Welfare Department, Government of Kerala","year":"2021"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.36713\/epra2013"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02405-1"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2013.07.011"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00997-x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.12.032"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3000003"}],"container-title":["Tropical Medicine &amp; International Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tmi.13979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T09:14:16Z","timestamp":1714986856000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tmi.13979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1111\/tmi.13979"],"URL":"https:\/\/doi.org\/10.1111\/tmi.13979","archive":["Portico"],"relation":{},"ISSN":["1360-2276","1365-3156"],"issn-type":[{"value":"1360-2276","type":"print"},{"value":"1365-3156","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2024-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}